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The PDGFRα-laminin B1-keratin 19 cascade drives tumor
progression at the invasive front of human hepatocellular
carcinoma
O Govaere1,2,7, M Petz3,7, J Wouters1, Y-P Vandewynckel4, EJ Scott2, B Topal5, F Nevens6, C Verslype6, QM Anstee2, H Van Vlierberghe4,
W Mikulits3,7 and T Roskams1,7
Human hepatocellular carcinomas (HCCs) expressing the biliary/hepatic progenitor cell marker keratin 19 (K19) have been linked
with a poor prognosis and exhibit an increase in platelet-derived growth factor receptor α (PDGFRα) and laminin beta 1 (LAMB1)
expression. PDGFRα has been reported to induce de novo synthesis of LAMB1 protein in a Sjogren syndrome antigen B (La/SSB)-
dependent manner in a murine metastasis model. However, the role of this cascade in human HCC remains unclear. This study
focused on the functional role of the PDGFRα-La/SSB-LAMB1 pathway and its molecular link to K19 expression in human HCC. In
surgical HCC specimens from a cohort of 136 patients, PDGFRα expression correlated with K19 expression, microvascular invasion
and metastatic spread. In addition, PDGFRα expression in pre-operative needle biopsy specimens predicted poor overall survival
during a 5-year follow-up period. Consecutive histological staining demonstrated that the signaling components of the PDGFRα-La/
SSB-LAMB1 pathway were strongly expressed at the invasive front. K19-positive HCC cells displayed high levels of α2β1 integrin
(ITG) receptor, both in vitro and in vivo. In vitro activation of PDGFRα signaling triggered the translocation of nuclear La/SSB into the
cytoplasm, enhanced the protein synthesis of LAMB1 by activating its internal ribosome entry site, which in turn led to increased
secretion of laminin-111. This effect was abrogated by the PDGFRα-speciﬁc inhibitor crenolanib. Importantly LAMB1 stimulated ITG-
dependent focal adhesion kinase/Src proto-oncogene non-receptor tyrosine kinase signaling. It also promoted the ITG-speciﬁc
downstream target Rho-associated coiled-coil containing protein kinase 2, induced K19 expression in an autocrine manner,
invadopodia formation and cell invasion. Finally, we showed that the knockdown of LAMB1 or K19 in subcutaneous xenograft
mouse models resulted in signiﬁcant loss of cells invading the surrounding stromal tissue and reduced HepG2 colonization into
lung and liver after tail vein injection. The PDGFRα-LAMB1 pathway supports tumor progression at the invasive front of human HCC
through K19 expression.
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INTRODUCTION
Liver cancer is the ﬁfth most diagnosed cancer worldwide
with an increasing incidence each year, making it the second
leading cause of cancer-related death globally.1 Hepatocellular
carcinoma (HCC) represents the major histologic type of primary
liver cancer, accounting for 70–85% of the total liver cancer. About
80% of HCCs arise in a background of long-lasting chronic
liver disease, making this a heterogeneous disease depending
on the underlying etiology and stage of the chronic disease.2
The Barcelona Clinic Liver Cancer classiﬁcation system is widely
used to stage patients and to guide therapeutic decisions.3
Only a minority of the patients are eligible for surgical resection
or transplantation, largely because of the fact that the
majority of HCCs are diagnosed at an advanced stage with
macrovascular invasion or metastases.4 This translates to a
5-year survival of o15% for patients diagnosed with HCC.
To date, Sorafenib is the only approved drug for systemic
treatment of advanced HCC but confers only a modest survival
beneﬁt.5
In recent years, tremendous efforts have been made to stratify
human HCCs based on molecular proﬁles.6–8 Although molecular
classiﬁcation of HCC turned out to be useful to predict the
outcome of the patient, it has not yet proven helpful in guiding
therapeutic choices and management over time.3 Hoshida and
colleagues9 showed that the gene expression signature in
adjacent tissue to HCC correlates with survival, rather than the
gene signature from the tumors themselves. This suggests that
tumor-surrounding interaction is a pivotal factor in patient-speciﬁc
prognosis and the progression of HCC. Animal models have
shown that the platelet-derived growth factor (PDGF) axis is
important in maintaining the invasive phenotype of HCC at the
tumor edge.10 Accordingly, the PDGF receptor alpha (PDGFRα) has
been reported to be elevated in human HCC samples, especially in
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patient samples diagnosed with microvascular invasion.11,12
Notably, our recent studies revealed that PDGFRα signaling
upregulates the expression of the extracellular matrix protein
laminin beta 1 (LAMB1) in a murine model of HCC invasion.13
LAMB1 is a speciﬁc β-chain isoform, which can form, together with
an α and γ chain, a trimeric laminin protein that is mainly
distributed along the basement membrane. Investigating the
regulation of LAMB1 translation, we found that the leader region
of the LAMB1 mRNA contains a structural RNA motif that acts as
an internal ribosome entry site (IRES) and is regulated by the IRES-
transacting factor Sjogren syndrome antigen B (La/SSB).14 PDGFRα
induces the translocation of nuclear La/SSB to the cytoplasm,
leading to IRES activation and the increase of LAMB1 de novo
protein synthesis.13 We found that this PDGF-La/SSB-LAMB1 axis is
induced and maintained by transforming growth factor-β during
murine metastasis. In human HCC, we reported that PDGFRα and
LAMB1 are associated with keratin (K) 19 expression.15 The
expression of the biliary/hepatic progenitor cell (HPC) marker
keratin 19 (K19) is linked with poor prognostic clinicopathological
features, such as microvascular invasion, metastasis and early
recurrence.15,16
This study focuses on the functional role of the PDGFRα-
LAMB1 pathway and its molecular link to K19 expression in
human HCC progression. We show that PDGFRα expression is
increased at the invasive front of human HCC. In vitro activation
of PDGFRα leads to translational activation of LAMB1, which in
turn induces an invasive and metastatic phenotype of tumor
cells exhibiting K19 expression. Our ﬁndings provide evidence
that K19 expression is inducible in human HCC as a sign of
tumor progression.
RESULTS
Components of the PDGFRα-La/SSB-LAMB1 signaling pathway are
co-expressed at the invasive front of human HCC
In order to evaluate the clinicopathological and prognostic
signiﬁcance of PDGFRα expression, two retrospective, consecu-
tive cohorts were included in this study: one consisting out of
surgical specimens (n = 136) and one out of needle biopsies
(n = 46). In the cohort of 136 HCC patients, PDGFRα protein
expression was observed at the cellular membrane in 66.2% of
the samples (90/136) and correlated signiﬁcantly with micro-
vascular invasion (Po0.001), metastasis (Po0.001), tumor size
(Po0.05) and K19 expression (Po0.001) (Table 1). No correla-
tion was found with etiology, differentiation grade or cirrhosis.
PDGFRα expression was increased at the invasive front in 54.5%
of the cases (48/88; Po0.0001), especially in HCCs displaying
microvascular invasion (44/80; Po0.0001) (Figures 1a and b). In
all, 26.1% of the PDGFRα-negative HCCs (12/46) were diagnosed
as early HCC compared with only 3.3% of the PDGFRα-positive
samples (3/90), suggesting that PDGFRα expression may be
linked with tumor progression. As the surgical samples were
obtained from patients undergoing resection or transplantation,
an end-stage treatment, the prognostic value of PDGFRα was
analyzed in a cohort of 46 diagnostic needle biopsies with a
follow-up exceeding 5 years. In this cohort, PDGFRα expression
correlated with poor overall survival (Po0.01) (Figure 1c) and
K19 expression (Po0.05) (Supplementary Table S1). We recently
described the PDGFRα-dependent translational control of
LAMB1 through the translocation of the La/SSB from the
nucleus to the cytoplasm and by binding of La/SSB to the
LAMB1-IRES in a murine model of HCC progression.13 To
examine whether the PDGFRα/LAMB1 mechanism is relevant
in human HCC, 15 patient samples with microvascular invasion
Table 1. Clinical and pathological features of HCC patients (n= 136) with correlation to PDGFRA expression
PDGFRA positive PDGFRA negative
Immunopositivity 66.18% (90/136) 33.82% (46/136)
Age (years) (mean) 63.09 (NS) 60.74 (NS)
Gender
Male 68.89% (62/90; NS) 71.74% (33/46; NS)
Female 31.11% (28/90; NS) 28.26% (13/46; NS)
Etiology
HBV 5.56% (5/90; NS) 10.87% (5/46; NS)
HCV 24.44% (22/90; NS) 32.61% (15/46; NS)
HBV+HCV 1.11% (1/90; NS) 6.52% (3/46; NS)
ALD 13.33% (12/90; NS) 17.39% (8/46; NS)
ALD+viral infection 2.22% (2/90; NS) 0% (0/46; NS)
Other 36.66% (33/90; NS) 19.57% (9/46; NS)
Unknown 16.67% (15/90; NS) 13.04% (6/46; NS)
Microvascular invasion 78.89% (71/90; Po0.001) 19.57% (9/46; NS)
Metastasis 68.18% (45/66; Po0.001) 20.59% (7/34; NS)
Tumor size (cm; mean) 5.75 (Po0.05) 3.83
K19 expression 14.44% (13/90; Po0.001) 0% (0/46; NS)
early HCCs 3.33% (3/90; NS) 26.09% (12/46; NS)
Differentiation grade
Well 28.89% (26/90) 6.52% (3/46)
Moderate 44.44% (40/90) 32.61% (15/46)
Poorly 26.67% (24/90) 60.87% (28/46)
Cirrhosis
No 33.33% (30/90; NS) 15.22% (7/46; NS)
Yes 65.56% (59/90; NS) 82.61% (38/46; NS)
Unknown 1.11% (1/90; NS) 2.17% (1/46; NS)
Abbreviations: ALD, alcoholic liver disease; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NS, not signiﬁcant; PDGFRA, platelet-
derived growth factor receptor α. Bold values indicate signiﬁcance.
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Figure 1. PDGFRα-La/SSB-LAMB1 pathway is expressed at the invasive front of human HCCs. (a) Representatitve example of PDGFRα
immunohistochemistry in a human HCC sample showing increased expression at invasive front and at sites of microvascular invasion
compared with the tumor bulk. (b) Diagram, quantiﬁcation of PDGFRα levels at the tumor bulk, border and at sites of microvascular invasion in
surgical HCC samples (n= 136). PDGFRα expression is signiﬁcantly increased at the tumor border and is associated with microvascular invasion
(Fisher’s exact, Po0.0001). (c) Predictive value of PDGFRα expression in needle biopsies (n= 46). PDGFRα positivity is associated with a poor
overall survival (log-rank Mantel–Cox test, P= 0.0011). (d) Examples of sequential histological stainings showing the co-expression of PDGFA,
PDGFRα, cytosolic La/SSB and LAMB1 in HCCs with microvascular invasion (n= 15). Two representative examples (patient 1 and patient 2) with
stromal and microvascular invasion show a high expression of members of the PDGFRα-La/SSB-LAMB1 cascade.
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were sequentially stained for PDGFα, PDGFRα, La/SSB and
LAMB1. PDGFα was strongly expressed in blood vessels
surrounding the tumor and was seen focally on the membrane
of tumor cells at the invasive front (Figure 1d). In addition, the
invasive front not only showed a high PDGFRα expression but
also a strong cytoplasmic La/SSB expression compared with the
bulk of the tumor where a nuclear La/SSB expression was
predominant (Figure 1d, Supplementary Figure S1). In areas with
Figure 2. IRES-mediated translation of LAMB1 is enhanced by PDGF. HepG2 and SNU-423 cells were treated for 24 h with PDGFA/B ligand or
crenolanib, a speciﬁc inhibitor of PDGFRα activation. Cells were additionally stimulated with PDGFA/B 15 or 30 min before cell lysis. (a) Western
blot analysis showing PDGFRα phosphorylation and expression of LAMB1. Actin was used as loading control. The diagram in the lower panel
shows relative values of pPDGFRα/PDGFRα and LAMB1/Actin of the quantiﬁed western blot (n= 3). Signal intensities of untreated cells were
set to a value of 1 for normalization. (b) Western blot analysis shows that small interfering RNA (siRNA)-mediated knockdown of PDGFRα in
HepG2 cells inhibits the increase of LAMB1 expression upon PDGF A/B treatment. A non-targetting siRNA (siNT) was used as a control (n= 3).
(c) qPCR of LAMB1 expression (n= 4). (d) HepG2 cells were transfected with a bicistronic vector containing the LAMB1 5’-UTR in the
intercistronic region between the upstream β-galactosidase (β-gal) and downstream chloramphenicol acetyltransferase (CAT) reporter.
Reporter activities were measured 48 h after transfection (n= 3). CAT reporter levels showing IRES activity were normalized to β-gal levels
representing the transfection efﬁciency. The empty vector was used for control (ctrl). (e) The subcellular localization of La/SSB was analyzed by
western blotting of cytoplasmic (c) and nuclear (n) fractions (n= 3). Tubulin and nucleoporin served as cytoplasmic or nuclear marker.
(f) Western blot analysis showing LAMB1 and Ln-111 levels in cell lysate (cells) or supernatant (sn) (n= 3). Actin was used as loading control. All
data are presented as means± s.d. and analyzed using the Student’s t-test (*Po0.05, **Po0.01, ***Po0.005).
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cytoplasmic La/SSB positivity, LAMB1 expression was observed
in the cytoplasm and the extracellular surroundings of tumor
cells, indicating that the PDGFRα-La/SSB-LAMB1 signaling path-
way is active at the invasive front.
PDGF regulates Ln-111 secretion in human HCC cell lines
In order to validate the results observed in human samples, the
PDGFRα-La/SSB-LAMB1 cascade was investigated in vitro. HepG2
and SNU-423 human hepatoma cells expressed detectable levels
of both PDGFRα and PDGFRβ on RNA and protein level
(Supplementary Figure S2). Both HCC cell types responded to
PDGFA/B stimulation by Y754-phosphorylation of PDGFRα and
increased expression of LAMB1 (Figure 2a). This effect was
abolished by simultaneous treatment with the speciﬁc PDGFRα
inhibitor crenolanib, indicating that LAMB1 expression depends
on the activation of PDGFRα.17
Albeit PDGFRβ is expressed at low levels in HepG2 compared
with SNU-423, both cell lines respond to PDGFA/B stimulation with
a comparable upregulation of LAMB1 expression. Knockdown of
PDGFRα in HepG2 abolished the effect of PDGFA/B, indicating that
PDGFRα is the limiting factor in regulating LAMB1 expression
(Figure 2b). Quantitative PCR (qPCR) analysis revealed that the
mRNA expression of LAMB1 is not affected by the modulation of
the PDGF signaling, suggesting a regulation at the level of mRNA
translation (Figure 2c). Thus, we analyzed the IRES regulation of
LAMB1 with a bicistronic reporter assay and found that the LAMB1-
IRES activity is enhanced by PDGF stimulation (Figure 2d). This
effect was reduced in the presence of the crenolanib. Accordingly,
the cytoplasmic accumulation of La/SSB was induced by PDGFA/B
and impaired by crenolanib treatment in both HepG2 and SNU-423
cells, as shown by the shifts of western blot signals—because of
posttranslational modiﬁcations—from nuclear to cytoplasmic
fractions (Figure 2e). As LAMB1 is the β1-subunit of laminin-111
(Ln-111), which is the predominant laminin isoform found in the
liver, we next questioned whether the LAMB1 assembling into
Ln-111 is regulated by PDGF. Immunodetection of whole-cell
lysates and cell culture supernatants revealed that PDGF elevated
LAMB1 expression and resulted in increased secretion of Ln-111
(Figure 2f). Taken together, these data show that activation of
PDGFRα signaling triggers the translocation of nuclear La/SSB into
the cytoplasm where it enhances LAMB1-IRES translation.
Enhanced LAMB1 expression leads to increased secretion of
Ln-111.
K19 expression is driven by an autocrine Ln-111 loop
As PDGFRα expression signiﬁcantly correlated with K19 expression
(Table 1 and Supplementary Table S1), we investigated whether
PDGFRα-La/SSB-LAMB1/Ln-111 and K19 regulation are molecularly
linked. Western blot and immunocytochemical analyses showed
that HepG2 and SNU-423 cells respond to Ln-111 treatment by
upregulating K19 expression (Figures 3a and e). K19 levels were
reduced by the simultaneous treatment with an inhibitory Ln-111
antibody. In addition, PDGFA/B elevated K19 expression was
reduced in the presence of crenolanib (Figure 3b). PDGFA/B and
Ln-111 stimulation induced KRT19 mRNA, indicating regulation at
transcriptional level (Figures 3c and d). In silico analysis identiﬁed
TEA domain transcription factor 4 (TEAD4) as a candidate
transcriptional regulatory element of KRT19 (Supplementary
Table S2 and Supplementary Figure S3). Upon Ln-111 coating,
TEAD4 shifted from the cytoplasm to the nucleus, suggesting
transcriptional activity (Supplementary Figure S3). Treatment with
collagen-1, which can partly signal through the same integrin (ITG)
Figure 3. Secretion of Ln-111 stimulates K19 expression. (a) HepG2 and SNU-423 cells were cultured on plastic or Ln-111-coated dishes in the
presence or absence of an inhibitory antibody speciﬁc for Ln-111. Lysates were taken after 24 h and analyzed for K19 expression by western
blotting (n= 3). (b) Western blot analysis of cells treated with PDGFA/B or PDGFRα inhibitor crenolanib for 24 h (n= 3). (c, d) qPCR analysis of
cells treated with PDGFA/B, crenolanib or Ln-111 coating. (n= 4, data are presented as means± s.d. and analyzed using the Student’s t-test,
*Po0.05, **Po0.01) (e) The effect of Ln-111 coating on K19 expressing was visualized using immunocytochemistry (n= 4, Scale bar 100 μm).
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Figure 4. Ln-111 activates ITG signaling and downstream ROCK2. (a) HCC cell lines were analyzed for ITG receptor expression by PCR or
(b) qPCR. (c) K19 levels of HCC cell lines cultured on plastic or Ln-111-coated dishes were detected by western blot analysis. (d) HepG2 and
SNU-423 cells were cultured on plastic or Ln-111-coated dishes in the presence or absence of an inhibitory antibody speciﬁc for Ln-111. The
medium was replaced with serum-free medium after 12 h. Lysates were taken after 24 h and analyzed by western blotting. For the fetal calf
serum (FCS)-positive control, 10% FCS were added to the media 30 min before cell lysis. Ln-111 coating induced the phosphorylation of ITG-
speciﬁc downstream proteins focal adhesion kinase (FAK), Src and ROCK2. The diagram in the lower panel shows relative values of pFAK/FAK,
pSrc/Src and pROCK2/ROCK2 of the quantiﬁed western blot (n= 3). Signal intensities of untreated cells were set to a value of 1 for
normalization. (e) Representative HCC sample showing strong positivity for LAMB1, ITGA2 and ITGB1, and focal positivity for K19 in invading
tumor cells located in a blood vessel (scale bars 100 μm). (f) Sequential stainings for PDGFRα, cytosolic La/SSB, LAMB1, ITGA2, ITGB1 and K19
were performed on 15 HCC samples with microvascular invasion and scored for immunopositivity. All data are presented as means± s.d. and
analyzed using the Student’s t-test (*Po0.05, **Po0.01, ***Po0.005).
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receptors as Ln-111, did not affect K19 expression (Supplementary
Figure S4). From these data, we conclude that extracellular Ln-111
activates K19 expression.
K19 is inducible in α2β1 ITG-positive HCC cells
Ln-111 mainly signals by binding to ITG receptors. Several HCC cell
lines were analyzed for ITG expression using PCR/qPCR to
investigate which receptors correlate with Ln-111-induced K19
expression (Figures 4a and b). HepG2 and SNU-423 cells showed
high expression of the subunits ITGA2 and ITGB1, which can form
the α2β1 ITG receptor. Notably, only these cell lines responded to
Ln-111 stimulation by upregulation of K19 (Figure 4c). Further-
more, Ln-111 activated the ITG-dependent focal adhesion kinase/
Src proto-oncogene non-receptor tyrosine kinase (Src) signaling
and the ITG-speciﬁc downstream target Rho-associated coiled-coil
containing protein kinase 2 (ROCK2, Figure 4d). Sequential
immunohistochemical stainings in human HCC samples with
microvascular invasion (n= 15) showed a strong positivity for
ITGA2 and ITGB1 at the invasive front, where also LAMB1 was
noted (Figures 4e and f). K19 showed a focal positivity at the
invasive front of four HCCs, suggesting that K19 is a sign of
advanced tumor progression (Figure 4e and Supplementary
Figure S1). In addition, the prognostic value of ITGA2, ITGB1,
TEAD4 and KRT19 gene expression was validated in a cohort of 370
human patients obtained from the Cancer Genome Atlas. The
four-gene signature stratiﬁed patients into groups with poor
overall survival (n= 370, Po0.05) and early recurrence (n= 319,
Po0.01) (Supplementary Figure S5).
LAMB1/Ln-111 promotes invasion and invadopodia formation
As LAMB1 is detected at the invasive front of human HCCs and
induces K19 expression, a marker associated with microvascular
invasion and metastasis, we investigated the functional role of
LAMB1 on cell invasion. Stable transfection of the SNU-423 cells and
Figure 5. Ln-111 promotes invasion and invadopodia formation. (a) Expression of short hairpin RNA (shRNA) targeting LAMB1 (shLAMB-27,
shLB1-29) or KRT19 (shK19-44, shK19-73) resulted in a stable knockdown and reduced protein expression as shown western blotting.
Non-target shRNA (shNT) was used as control. (b) LAMB1 (shLB1-27) or K19 (shK19-44) knockdown reduced the formation of invadopodia in
SNU-423 cells, whereas PDGF A/B treatment slight increased invadopodia (NC, negative control; scale bars 50 μm). (c, d) SNU-423 and HepG2
cells were subjected to a collagen Boyden chamber-based invasion assay (n= 3, t= 72 h). OD, optical density; all data are presented as
means± s.e.m. relative to the untreated control and analyzed using the Student’s t-test compared to the control (*Po0.05).
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HepG2 cells with short-hairpins directed against LAMB1 and KRT19
resulted in lower protein expression (Figure 5a). Both LAMB1- and
K19-knockdown reduced invadopodia formation in SNU-423 cells,
whereas PDGFA/B treatment mildly stimulated formation (Figure 5b).
As SNU-423 cells express a high basal level of K19 (Figure 3e), we
used the SNU-423 cells as a model for Ln-111 inhibition, whereas
HepG2 cells were used as a model for Ln-111 stimulation. The LAMB1
knockdown resulted in a reduced capacity to invade through a
collagen membrane in the SNU-423 cells (Figure 5c). This effect was
restored when coating the collagen Boyden chamber with Ln-111
before seeding (Figure 5c). Ln-111 coating promoted invasion in the
HepG2 cells, which was repressed upon anti-Ln-111 antibody
treatment (Figure 5d). Knockdown of K19 reduced the capacity to
invade in both cells, when compared with the untreated control.
Figure 6. LAMB1 and K19 promote metastatic colonization. (a) HepG2 cells with a knockdown of LAMB1 (shLB1-27, shLB1-29) or K19
(shK19-44, shK19-73) or the non-target control (shNT) were subcutaneously injected into NSG mice. Shown are the average weights of
resected tumors (n= 8) after 50 days. (b) Immunohistochemical analysis showed a reduced number of single K19-positive cells undergoing
stromal invasion upon LAMB1- or K19- knockdown in the subcutaneous HepG2 xenograft mouse model (scale bars 100 μm). Cells at the tumor
border were quantiﬁed in ﬁve different high-power ﬁeld. (c) HepG2 cells were injected into the tail vein of NSG mice (n= 4). Blood samples
and organs were taken after 42 days. Samples were homogenized, pooled and analyzed by PCR. The presence of HepG2 cells was determined
with a human-speciﬁc primer (RhoA h). Primers recognizing human as well as mouse RhoA (m/h) were used for normalization. Cultured
murine (MIM-R) and human (HepG2) cells were used as control. (d) RNA levels were quantiﬁed by ImageQuant software. Signal intensities of
shNT were set to a value of 1 for normalization. (e) Schematic overview. PDGFRα activation by PDGF A/B triggers the translocation of La/SSB
from the nucleus to the cytoplasm. La/SSB acts as ITAF and binds to the untranslated region of the LAMB1 mRNA to enhance IRES translation.
LAMB1 joins with α- and γ-subunits to form Ln-111. The secreted Ln-111 activates (α2β1) ITG driven focal adhesion kinase (FAK)/Src signaling
and regulates ROCK2 phosphorylation and K19 expression. All data are presented as means± s.d. and analyzed using the Student’s t-test
(*Po0.05, **Po0.01, ***Po0.005).
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LAMB1 and K19 provide metastatic features in vivo
We addressed the question whether K19 is in addition to being a
marker for patient survival actively involved in regulating tumor
progression. The effect of LAMB1- and K19-knockdown in
hepatoma cells was analyzed for tumor formation after xenograft-
ing. As SNU-423 cells were not tumorigenic, all in vivo experiments
were performed with HepG2 cells. Neither the knockdown of
LAMB1 nor of K19 inﬂuenced subcutaneous tumor growth of
HepG2 cells (Figure 6a and Supplementary Figure S6). In
accordance, we found that K19 or LAMB1 knockdown had no
effect on cell proliferation in vitro (Supplementary Figure S7). In
the control tissue derived from parental HepG2 cells, a few K19-
positive cells underwent stromal invasion at the tumor border,
which was lost upon knockdown of K19 or LAMB1 (Figure 6b). We
further analyzed the ability of LAMB1- or K19-targeted HepG2 cells
for metastatic colonization after tail vein injection. Blood samples
and organs were analyzed by PCR with primers speciﬁc for human
RhoA. Primers that detect both human and mouse RhoA were
used for normalization. This analysis showed that knockdown of
K19 signiﬁcantly reduced HepG2 colonization into the lung and
liver (Figures 6c and d), suggesting that intervention with K19
expression negatively affects the abilities of HCC cells to
extravasate and colonize distal tissues.
DISCUSSION
The expression of PDGFRα has previously been associated with
metastasis and increased recurrence in patients diagnosed with
HCC.11,12 In vitro, PDGFRα has been reported to promote
invadopodia formation and invasion, though the exact mechan-
ism is unclear.18 Using a large cohort of HCC samples, this study
shows that PDGFRα expression was strongly associated with
microvascular invasion, metastatic spread and K19 expression.
PDGFRα expression was especially increased at the tumor border,
implying a communication between the tumor and its surround-
ings. The ligand PDGFα was strongly expressed by surrounding
blood vessels suggesting that endothelial cells may inﬂuence
tumor behavior. Abnormal angio-architecture and angiogenesis is
distinctive for end-stage liver cirrhosis and may be necessary to
sustain HCC progression.19,20 Our results shows that activation of
PDGFRα leads to LAMB1 deposition in a La/SSB-dependent
manner, irrespective of the levels of PDGFRβ. We suggest that
PDGFRα signaling activates the translocation of La/SSB from the
nucleus to the cytoplasm where it interacts with the IRES motif of
LAMB1 mRNA, enhancing the translation, which results in an
increased expression of Ln-111 (Figure 6e). In human HCC
samples, a cytoplasmic La/SSB and LAMB1 positivity was mainly
seen in invasive epithelial tumor cells, indicating that these cells
generate their own microenvironment. Many subtypes of laminins
have been described to promote cell adhesion and migration via
ITG interaction.21 Our results show that LAMB1 has an effect on
HCC cell lines expressing the α2β1 ITG receptor by activating focal
adhesion kinase/Src and ROCK2. ROCK2 is a regulator of the actin
cytoskeleton and cell polarity and has been implemented in
metastasis and invasion of human HCC.22 In addition, LAMB1
induces a phenotype switch resulting in increased expression of
the biliary/HPC marker K19, probably regulated by the transcrip-
tion factor TEAD4. TEAD4 can form a binding complex with yes-
associated protein 1, which has been reported to induce hepatic
progenitor features in regenerating liver and to be a downstream
target of ITGB1 in activated hepatic stellate cells.23,24 Our results
show that the ITGA2-ITB1-TEAD4-KRT19 gene signature has
prognostic value, presumably reﬂecting the activation of the
PDGFRα cascade in α2β1 ITG-positive human HCC.
The occurrence of K19, a biliary/HPC marker, has been widely
described as a poor prognostic marker in human HCC as it
correlates with microvascular invasion, metastatic spread, poor
differentiation, early recurrence and consequently poor overall
survival.16,25–28 It has been an on-going debate whether K19
reﬂects an HPC origin or is a sign of tumor progression. Using a
diethylnitrosamine-induced liver tumor mouse model, Mu and
colleagues29 showed that K19 arises because of dedifferentiation
rather than ﬁnding its origin in an HPC. This study supports the
ﬁnding that K19 is inducible but, moreover, it shows that LAMB1-
mediated K19 expression correlates with invasion and metastasis.
Why tumor cells start expressing K19 is still not completely clear.
One explanation may be that speciﬁc members of the cytoske-
leton act as an anchor point for actin ﬁlaments to form
invadopodia and promote invasion and hence explains the
phosphorylation of ROCK2. Another hypothesis may be that
tumor cells are protecting themselves by inducing K19 and
‘educating’ themselves for successful metastasis. In chronic liver
disease, hepatocytes can dedifferentiate under stress by expres-
sing biliary markers, a phenomenon called metaplasia.30,31 In
human HCC, knockdown of K19 has been linked with increased
sensitivity to chemotherapy, suggesting that K19 also has a
protective role.15 Our results underline the importance of K19 in
metastasis as its loss signiﬁcantly reduced tumor colonization in
different organs.
PDGFRα has been reported to be one of the genes to distinguish
dysplastic lesions from early HCC.32 Histologically, stromal invasion
is a diagnostic criterion for the differentiation from high-grade
dysplastic nodule toward an early HCC.33 Although in this study
most of the early HCCs displayed no PDGFRα expression on
protein level, it is very likely that the PDGFRα-LAMB1 pathway
becomes activated during tumor progression. This would explain
why K19 is only reported in minority of human HCC and strongly
links with features of advanced tumor stage. This offers novel
therapeutic possibilities to already intervene at an early stage of
the disease by inhibiting PDGFRα, using crenolanib, or by
targeting speciﬁc ITG receptors (for example, ITGA2).
Nevertheless, showing that K19 is inducible and reﬂects tumor
progression, does not exclude that HPCs can be a source for
hepatic cancer.34 Whether HPCs are more prone to form HCCs or
rather mixed HCC/cholangiocellular carcinomas still needs be
investigated further. Scattered K19-positive cells found in the
tumor bulk of human HCCs have been suggested to harbor
‘stemness-like’ properties.34 This underlines the complexity and
heterogeneity of human HCCs. At this stage, liver cancer research
is limited because of the lack of suitable metastatic mouse HCC
models and by the fact that most human HCC samples used for
research purposes are obtained through an end-stage treatment
(that is, resection or transplantation). In mice, the
diethylnitrosamine-induced liver cancer model is widely used
but it is a model for tumor initiation and growth, lacking invasion
and metastasis. Tail vein injection gives you the opportunity to
study circulating tumor cells and possible distant metastases, yet it
lacks ‘the niche’ of a chronic diseased liver to sustain new tumor
formation. The SNU-423 cell line proved highly invasive in vitro but
lacked the capacity to grow subcutaneously. This emphasizes the
need for future research to take in account the different stages of
liver cancer: that is, carcinogenesis, invasion and metastasis, and
this on a background of chronic liver disease.
Overall, this study shows that the PDGFRα-LAMB1 pathway has
a crucial role in the invasion and metastasis of human HCC
through the induction of K19. Not only have several members of
this cascade proven to be of prognostic value, but also these
results offer the prospect of targeting the cascade at different
levels to treat patients at an earlier stage of the disease.
MATERIALS AND METHODS
Patient selection
In all, 182 formalin-ﬁxed parafﬁn-embedded HCC samples were included in
this study. Patients were diagnosed with HCC based on the WHO
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classiﬁcation and treated at the University Hospitals Leuven between 2004
and 2008. The cohort of 136 surgical specimens was obtained after
resection or transplantation. Each patient gave informed consent. In case
of multiple nodules per patient (for example, satellite nodules in explant
livers), the largest HCC nodule was considered as the representative
sample. Marker expression was correlated with clinicopathological para-
meters: tumor size, tumor differentiation, microvascular invasion and
metastasis. Microvascular invasion was scored in the tumor and the
surrounding area; positivity for metastasis was established using histo-
pathological evaluation and/or based on available clinical data (100 of the
136). A total of 46 needle biopsies were taken for diagnostic purpose or
before a surgical procedure. Patients had a follow-up exceeding 5 years to
determine the overall survival. This study was approved by the UZLeuven-
KU Leuven Biobank and the ethical committee of the University Hospitals
Leuven, Belgium.
Immunohistochemistry
Formalin-ﬁxed parafﬁn-embedded human and mouse samples were
stained using the Bond Polymer Reﬁne Detection kit on the Bond Max
autostainer (Leica, Microsystems GmbH, Wetzlar, Germany). Primary
antibodies were directed against PDGFA (1:100, Santa Cruz Biotechnology,
Dallas, TX, USA, 9974), PDGFRα (1:100, Abcam, Cambridge, UK, ab61219),
La/SSB (1:50, Santa Cruz Biotechnology, 33593), LAMB1 (1:100, Santa Cruz
Biotechnology, 17763), ITGA2 (1:200, Santa Cruz Biotechnology, 74466),
ITGB1 (1:100, Abcam, ab24693) and K19 (1:25, Dako, Glostrup, Denmark,
RCK108).
Cell culture
All human hepatoma cell lines were obtained from ECACC (Salisbury, UK)
and authenticated by short tandem repeat analysis. Human SNU-423 and
SNU-475 cells, and murine MIM-R hepatoma cells were cultured in RPMI
1640 plus 10% fetal calf serum.10 Human HEP3B, HepG2, HUH7 and PLC/
PRF/5 cells were propagated in Dulbecco’s modiﬁed Eagle’s medium plus
10% fetal calf serum at 37 °C and 5% CO2. Cell lines were tested monthly
for mycoplasma contamination using MycoFluor Mycoplasma Detection Kit
(Invitrogen, Carlsbad, CA, USA). Cells were treated with 20 ng/ml PDGFA/B
(PeproTech, Rocky Hill, NJ, USA, 100-00AB) or 50 nM crenolanib (Sell-
eckchem, Houston, TX, USA, CP-868596) for stimulation or inhibition of
PDGF signaling, respectively. For stimulation of laminin signaling, culture
dishes were coated for 1 h with 10 μg/ml Ln-111 (Sigma-Aldrich, St Louis,
MO, USA, L2020) before seeding of the cells, whereas coated dishes were
incubated for 30 min with 2 μg/ml anti-laminin 1 antibody (Abcam,
ab7463) for inhibition.
Collagen invasion and invadopodia assay
HepG2 or SNU-423 cells were submitted to a QCM Collagen Cell Invasion
Assay 8 μm and a QCM Gelatin Invadopodia Assay Green (Millipore,
Billerica, MA, USA) according to supplier’s protocol. Fetal calf serum was
used as attractant; Boyden chambers were coated with 10 μg/ml Ln-111
before seeding. In all, 2 μg/ml anti-laminin 1 antibody (Abcam, ab7463)
was used for inhibition of Ln-111, 20 ng/ml PDGFA/B (PeproTech, 100-
00AB) for stimulating PDGF signaling.
Immunocytochemistry
Cells were processed into formalin-ﬁxed parafﬁn-embedded tissue blocks
using the Cellient Automated Cell Block System (Hologic, Bedford, MA,
USA) and processed for immunohistochemistry as described above. In
addition, coated and non-coated cells were stained for K19 (1:50, Dako,
RCK108) using Envision Flex anti-mouse secondary (Dako). Visualization
was done using 3-amino-9-ethylcarbazole, followed by a hematoxylin
counterstaining.
Immunoﬂuorescence
In vitro coated and non-coated cells were stained for TEAD4 (1:50, Abcam,
ab58310) and yes-associated protein 1 (1:50, Santa Cruz Biotechnology,
101199), followed by an incubation with a AlexaFluor-488 Goat anti-mouse
antibody (Invitrogen). Nuclei were stained with 4′, 6-diamidino-2-
phenylindole (Invitrogen).
Transient knockdown of PDGRα
ON-TARGET plus SMARTpool siRNA (Dharmacon, Lafayette, CO, USA) was
used to knockdown PDGFRα in HepG2 cells. The cells were transfected
with 40 nM small interfering RNA against PDGFRα (L-003162-00-0005) or
non-target small interfering RNA (D-001810-10) using Oligofectamin
(Invitrogen, 12252011). The transfected cells were treated with 20 ng/ml
PDGFA/B (PeproTech, 100-00AB) and cell lysates were further processed for
western blot analysis 48 h post transfection.
Stable knockdown of LAMB1 and K19
HepG2 and SNU-423 cells were transduced with MISSION short hairpin
RNA lentiviral particles (Sigma-Aldrich) targeting LAMB1 (TRCN0000315627,
TRCN0000083429), KRT19 (TRCN0000062344, TRCN0000438673). A non-
targeting short hairpin RNA vector was used as control. Selection was done
by puromycin treatment.
Western blot analysis
Cell lysates were prepared with RIPA buffer (150 mM NaCl, 50 mM Tris pH
7.4, 0.5% sodium-deoxycholate, 1 mM β-glycerophosphate pH 7.2, 1%
nonidet P-40) supplemented with proteinase inhibitors (1 mM sodium
ﬂuoride, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonylﬂuorid,
10 μg/ml leupeptin and 10 μg/ml aprotinin). Nuclear and cytoplasmic
fractions were isolated using the previously described REAP method.35
Protein concentrations were determined by Bradford assay and a total of
20–30 μg protein was used for sodium dodecyl sulfate–polyacrylamide gel
electrophoresis. Primary antibodies against LAMB1 (Thermo Fisher
Scientiﬁc, Waltham, MA, USA, RT-796-P1), PDGFRα (Cell Signaling
Technologies, Danvers, MA, USA, 5241), phospho-PDGFRα (Cell Signaling,
Technology, 2992), K19 (Thermo Fisher Scientiﬁc, MS-1902-P1), Ln-111
(Abcam, ab7463), La/SSB (Santa Cruz Biotechnology, 33593), nucleoporin
(BD Biosciences, San Jose, CA, USA, 610498), tubulin (Sigma-Aldrich,
T5168), focal adhesion kinase (Santa Cruz Biotechnology, sc-558), phospho-
focal adhesion kinase (Invitrogen, 44652G), Src (Cell Signaling, USA, 2109),
phospho-Src (Invitrogen, 44660G), ROCK2 (Sigma-Aldrich, HPA007459),
phospho-ROCK2 (Abcam, ab83514) and actin (Sigma-Aldrich, A2066) were
used at a dilution of 1:1000. Peroxidase-conjugated secondary antibodies
(Vector Laboratories, Burlingame, CA, USA, PI-2000, PI-1000 and Santa Cruz
Biotechnology, sc-2006) were used for detection at a dilution of 1:10 000.
Western blots were quantiﬁed using ImageQuant software (Molecular
Dynamics, Chatsworth, CA, USA).
Computational analyses
Regulatory elements for KRT19 were obtained using GeneHancer (http://
www.genecards.org/Guide/GeneCard). Multi-gene biomarkers were corre-
lated with clinical outcome in a cohort of 370 patients based upon data
generated by the TCGA Research Network: http://cancergenome.nih.gov/.
Analysis was performed using the web-based tool cBioPortal.36,37 Publically
available ChIP-seq data for TEAD4 in HepG2 cells (GEO accession
GSM1010875) were downloaded from ChIP-Atlas (http://chip-atlas.org/).
BigWig and Peak-calls (qo1E-05) were visualized in the Integrative
Genomics Viewer.38
Transient transfection and bicistronic reporter assay
The bicistronic construct containing the LAMB1 5’-untranslated region
between a β-Gal and chloramphenicol acetyltransferase reporter or the
empty control vector were generated as outlined recently.14 Cells were
grown on a six-well plate and transfected with the vectors using
Lipofectamine Plus as recommended by the manufacturer (Invitrogen,
18324-020). The cells were lysed 48 h after transfection. β-Galactosidase
reporter activity was photometrically determined with o-nitrophenyl-b-D-
galactopyranoside. Chloramphenicol acetyltransferase activity was mea-
sured by enzyme-linked immunosorbent assay (Roche, Basel, Switzerland,
11363727001) as recommended by the manufacturer. The relative IRES
activity was calculated as ratio of chloramphenicol acetyltransferase
normalized to β-galactosidase activity.
Subcutaneous tumor formation and tail vein injection
In all, 5 × 106 HepG2 cells were resuspended in 200 μl Ringer solution and
subcutaneously injected into 8-week old immunodeﬁcient NSG (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) female mice (n= 8 per group) that were housed in
individually vented cages. Tumors were resected after 50 days. In total,
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1× 106 HepG2 cells resuspended in 100 μl Ringer solution were used for
tail vein injection (n= 4 per group). Blood samples and organs were taken
42 days after injection. Part of the tumor was ﬁxed in formalin and
processed into parafﬁn blocks, the rest of the samples were homogenized,
pooled and analyzed by PCR speciﬁc for human RhoA. Primers that detect
both human and mouse RhoA were used for normalization. Formalin-ﬁxed
parafﬁn-embedded samples were stained as described above. Cells were
quantiﬁed at the tumor border in ﬁve different ﬁelds (×200 magniﬁcation)
using the Nikon Eclipse software (Nikon Instruments Europe BV,
Amsterdam, Netherlands). Experiments were performed according to the
Austrian guidelines for animal care and protection.
Polymerase chain reaction (PCR) and qPCR
Total RNA was reverse transcribed in complementary DNA as recom-
mended by the manufacturer (Qiagen, Hilden, Germany). Aliquots of
complementary DNA were used for PCR using PuReTaq Ready-To-Go PCR
beads (GE Healthcare, Little Chalfont, UK, 27-9559-01) and evaluated by
agarose gel electrophoresis. PCR signals were densitometrically quantiﬁed
with ImageQuant 5.0 (GE Healthcare). qPCR was performed with Fast SYBR
green (Applied Biosystems, Foster City, CA, USA) and quantiﬁed with the
7500 Fast Real-Time PCR System (Applied Biosystems). Primer sequences
are shown in Supplementary Table S3.
Statistical analysis
Data were shown as average value ± s.d. The statistical signiﬁcance of
differences was evaluated using an unpaired Student’s t-test. Signiﬁcant
differences between experimental groups were *Po0.05, **Po0.01,
***Po0.005. Contingency analysis was done using the Fisher’s exact test
and the unpaired Student’s t-test with STATVIEW 5.0.1 software (SAS
Institute Inc., Cary, NC, USA).
ABBREVIATIONS
IRES, internal ribosome entry site; ITG, integrin; HCC, hepatocellular
carcinoma; HPC, hepatic progenitor cell; K/KRT, keratin; LAMB1,
laminin beta 1; La/SSB, Sjogren syndrome antigen B; Ln, laminin; PDGF,
platelet-derived growth factor; PDGFRα, platelet-derived growth factor
receptor α; ROCK2, Rho-associated coiled-coil containing protein kinase 2;
Src, Src proto-oncogene non-receptor tyrosine kinase; TEAD4, TEA domain
transcription factor 4.
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